Spinout Active LTD

Company profile

Ferryx Limited

UK company 12193693, incorporated on 6 September 2019.

Gut Health Supplements For A Calmer Digestive System | Ferrocalm

Improve your digestive system with Ferrocalm, a trusted gut health supplement for a calmer and healthier you.

Company number
12193693
Incorporated
6 Sep 2019
Companies House status
Active

Company identity

Browse spinouts
Founded / incorporated
6 September 2019

Company number 12193693

Verify at Companies House
Legal name
FERRYX LIMITED
Company type
LTD
Region
South West England
Registered address
Unknown
Insolvency history
No

Latest accounts

Financial period: 1 Oct 2023 to 30 Sep 2024

FILLETEDACCOUNTS
Turnover
Unknown
Profit / Loss
-£300,242
Employees
2

Company events

Reference milestones and recent Companies House filing stream events.

4 events
22 Sep
2026

Capital Allotment Shares

Capital

SH01 | Transaction MzU0NjI2NjkxM2FkaXF6a2N4

Published 22 Sep 2026 13:09

25 Aug
2026

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzU0MDgxNDc0MWFkaXF6a2N4

Published 25 Aug 2026 17:01

03 Aug
2026

Capital Allotment Shares

Capital

SH01 | Transaction MzUzNjY1NDY0OGFkaXF6a2N4

Published 03 Aug 2026 09:55

06 Sep
2019

Incorporated

Inception

Company registered at Companies House

Spinout profile

4 entries

Company description

Ferryx develops pharmaceuticals, designed to treat inflammatory conditions.

Ferryx are developing a safe and effective probiotic to prevent or treat gastrointestinal inflammation. Unlike many conventional probiotics, our proprietary strain thrives in the inflamed gut and exerts anti-inflammatory effects.

Project impact

Too early to record notable impacts.

FERRYX LIMITED
2019

Public funding

2 awards
First funded
2022
Funded years
2022, 2024
Age at first award
3 years

Projects

2024 Collaborative R&D Lead participant

Evaluation of the interactions of a novel live biotherapeutic product for the treatment of gut inflammation with the GI tract in an in vitro model

1 May 2024 to 30 Apr 2025

Awarded
£92,436
Total cost £92,436

There is a lack of satisfactory treatments for inflammatory bowel disease (IBD), an excruciating, debilitating condition which affects 1 in 123 people in the UK (\\\>0.5 million) and 6.8 million worldwide. Currently available treatments have significant negative side effects, affecting quality of life of patients and reducing compliance, leading to exacer...

2022 Grant for R&D Lead participant

Assessment of a multi strain live biotic feed additive in reducing environmental impact and improving productivity in chicken production

1 Nov 2022 to 31 Jan 2023

Awarded
£45,884
Total cost £45,884

The production of chicken to produce meat is responsible for the production of the greenhouse gas methane and the environmental pollutant ammonia. These are produced by the birds as they are reared and also by the litter that they live on. The bacteria that produce these chemicals live in the chicken's intestine. Any intervention that would reduce these b...

Product types

Collaborative R&D Grant for R&D